By Maxx Chatsko The drug developer finally agreed to a takeover offer from its majority shareholder after rejecting advances earlier this month. Persistence really does pay off after all. Women’s health drug specialist Myovant Sciences (MYOV) – Get Myovant Sciences Ltd. Report rejected a $2.5 billion acquisition from its largest shareholder, Japanese drugmaker Sumitomo Pharma, in early October. The finer details suggested shareholders might have been subjected to a roller coaster ride, or at the very least shouldn’t have expected a much higher offer. Shareholders were luckily spared the roller…